Biotechnology
Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
HANGZHOU and SHAOXING, China, Jan. 23, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) today announces the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). ASC40 is an oral, sele...
2022-01-23 18:35
3425
Sihuan Pharmaceutical (0460.HK): Establishment of Joint Venture with Bluepha Co., Ltd.
HONG KONG, Jan. 21, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group:" Hong Kong Stock Exchange Stock Code: 0460) is pleased to announce thatBeijing MeiYan KongJian...
2022-01-21 11:12
5024
Successful Groundbreaking Ceremony for GenScript ProBio to Expand Commercial cGMP Plasmid and Viral Vector Manufacturing Facility in Zhenjiang, China
ZHENJIANG, China, Jan. 20, 2022 /PRNewswire/ -- GenScript ProBio, a global antibody and gene therapy contract development and manufacturing organization (CDMO), has announced 2022 manufacturing expansion plans to meet the increasing demand for commercial cGMP plasmid and viral vector manufacturin...
2022-01-20 16:44
2417
Award: Boehringer Ingelheim is Global Top Employer 2022
* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the third consecutive year for the certification inIndonesia * High scores in values, ethics and integrity serve as a driver for a strong c...
2022-01-20 08:00
2435
Award: Boehringer Ingelheim is Global Top Employer 2022
* Boehringer Ingelheim advances to one of eleven global top employers worldwide * This is the second consecutive year for the global certification, and the second consecutive year for the certification inAustralia & New Zealand * High scores in values, ethics and integrity serve as a driver ...
2022-01-20 08:00
1760
Accomplished Pharma R&D leader, Sauri Gudlavalleti joins Sai Life Sciences as Chief Operating Officer
HYDERABAD, India, Jan. 19, 2022 /PRNewswire/ -- Sai Life Sciences, a leading
globalContract Research, Development & Manufacturing Organization
2022-01-19 18:30
2343
Novotech Completes $255M Private Placement Transaction and $505M Refinancing to Accelerate Implementation of Growth Initiatives
SINGAPORE and SYDNEY, Jan. 19, 2022 /PRNewswire/ -- Novotech Health Holdings Pte. Ltd. ("Novotech Holdings" or the "Company") today announced the completion of a financing round ofUS$760 million (about 1.06 billion AUD) comprising a US$255 million private placement and a US$505 million refinancin...
2022-01-19 16:38
1845
XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platform
HYDERABAD, India and SHENZHEN, China, Jan. 19, 2022 /PRNewswire/ -- Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based pharmaceutical biotechnology company r...
2022-01-19 09:00
7883
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerat...
2022-01-18 20:00
1590
e-BEAUTY LAUNCHES DNA TEST KITS FOR ASIANS
* Singapore-Based Company Develops Direct-to-Consumer DNA Test For Asians * Asian Screening Array Technology (ASA) Provides Most Accurate DNA Results for Asians * Online-to-Offline (O2O) Platform Allows Consumers to Submit Saliva Samples From Home SINGAPORE, Jan. 18, 2022 /PRNewswire/ -- Sin...
2022-01-18 16:09
1912
Genetech Biotechnology Launches Four Exclusive Promo Bundles For Citrea In Celebration Of Chinese New Year
* Half the price deals for Prosperity Bundle, Pampering Duo, CNY (Clean New Year) Pair and Abundance Combo, for a limited time only SINGAPORE, Jan. 18, 2022 /PRNewswire/ -- Genetech Biotechnology, the exclusive distributor of Citrea, launches four exclusive promo bundles to celebrate Chinese Ne...
2022-01-18 15:16
1733
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
HANGZHOU, China and SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing in its Phase2b clinica...
2022-01-18 08:00
2723
CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment
* Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in patients with metastatic gastric adenocarcinoma (GC)/gastro-esophageal junction (GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC) * A significant milestone in our pipeline development...
2022-01-18 08:00
3302
Seegene Continues to Support Israel's Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests toIsrael to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 mill...
2022-01-17 20:00
2242
HTPE Leads JYSSBIO to Close Series B+ Funding
HANGZHOU, China, Jan. 17, 2022 /PRNewswire/ -- Huatai International Private Equity Fund ("HTPE"), the Greater China focused private equity investment platform under Huatai Securities, is pleased to announce that it led the Series B+ financing ofZhejiang JYSS Bio-Engineering Co., Ltd. ("JYSSBIO" ...
2022-01-17 17:58
2890
The Philippines Has Approved ReCOV For Phase II/III Cinical Trial
* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial * ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta * Rhecogen , a subsidiary focused on mRNA vaccines of th...
2022-01-17 16:57
2391
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...
2022-01-15 08:00
4800
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
HANGZHOU and SHAOXING, China, Jan. 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme whic...
2022-01-13 17:30
3145
Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug de...
2022-01-13 13:33
2526
CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
* Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) * The National Medical Products Administration (NMPA) of China has granted the Breakthrough Therapy Designati...
2022-01-13 08:05
5727
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 309 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 280 media titles]
2024-05-03 06:25Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Most Read
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
3839
Ferretti's Dazzling Presence at the 2024 Singapore Yachting Festival: Showcasing Evolving Trends in Luxury Yachting
2024-04-28 15:02
2974
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2971
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
2024-04-28 09:39
2855